ASP2074 / Astellas - LARVOL DELTA

A Study of ASP2074 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=23 | Terminated | Sponsor: Astellas Pharma Global Development, Inc. | Active, not recruiting ➔ Terminated; Company Strategic Reasons

Metastases • Trial termination • Colorectal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

A Study of ASP2074 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=23 | Active, not recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Trial completion date: Dec 2027 ➔ Oct 2024 | Trial primary completion date: Sep 2027 ➔ Oct 2024

Metastases • Trial completion date • Trial primary completion date • Colorectal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

A Study of ASP2074 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=23 | Active, not recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Recruiting ➔ Active, not recruiting | N=193 ➔ 23

Enrollment change • Enrollment closed • Metastases • Colorectal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

ASP2074, a novel tetraspanin 8 x CD3 bispecific antibody, demonstrates selectivity and antitumor activity in preclinical cancer models. (AACR-NCI-EORTC 2023) - No abstract available

Preclinical • Oncology • TSPAN8

A Study of ASP2074 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=193 | Recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Trial primary completion date: Oct 2026 ➔ Sep 2027

IO biomarker • Metastases • Trial primary completion date • Colorectal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • CA 19-9 • CD8

A Study of ASP2074 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=193 | Recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • IO biomarker • Metastases • Colorectal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • CA 19-9 • CD8

A Study of ASP2074 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=193 | Not yet recruiting | Sponsor: Astellas Pharma Global Development, Inc.

IO biomarker • New P1 trial • Colorectal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • CA 19-9 • CD8